| 000 | 01699 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250518073436.0 | ||
| 264 | 0 | _c20210204 | |
| 008 | 202102s 0 0 eng d | ||
| 022 | _a1872-8332 | ||
| 024 | 7 |
_a10.1016/j.lungcan.2019.10.019 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMoldaver, Daniel | |
| 245 | 0 | 0 |
_aDevelopment, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model. _h[electronic resource] |
| 260 |
_bLung cancer (Amsterdam, Netherlands) _c01 2020 |
||
| 300 |
_a185-194 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Validation Study | ||
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xeconomics |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xmetabolism |
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xdrug therapy |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHealth Care Costs |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aModels, Statistical |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aSurvival Rate |
| 700 | 1 | _aHurry, Manjusha | |
| 700 | 1 | _aEvans, William K | |
| 700 | 1 | _aCheema, Parneet K | |
| 700 | 1 | _aSangha, Randeep | |
| 700 | 1 | _aBurkes, Ronald | |
| 700 | 1 | _aMelosky, Barbara | |
| 700 | 1 | _aTran, Diana | |
| 700 | 1 | _aBoehm, Darryl | |
| 700 | 1 | _aVenkatesh, Jaya | |
| 700 | 1 | _aWalisser, Susan | |
| 700 | 1 | _aOrava, Erik | |
| 700 | 1 | _aGrima, Daniel | |
| 773 | 0 |
_tLung cancer (Amsterdam, Netherlands) _gvol. 139 _gp. 185-194 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.lungcan.2019.10.019 _zAvailable from publisher's website |
| 999 |
_c30396857 _d30396857 |
||